UBX-363

UBX-363 is an orally bioavailable, small-molecule proteolysis-targeting chimera (PROTAC) designed to induce the degradation of Lymphocyte-specific protein tyrosine kinase (LCK). Developed by Ubix Therapeutics, it targets the over-activation of preTCR-LCK signaling, which is a known therapeutic vulnerability in approximately 44% of T-cell acute lymphoblastic leukemia (T-ALL) cases. Unlike traditional LCK inhibitors like dasatinib, UBX-363 utilizes the ubiquitin-proteasome system to achieve sustained protein depletion, demonstrating superior anti-proliferative activity in both dasatinib-sensitive (HSB-2) and dasatinib-insensitive (CCRF-CEM) T-ALL cell lines. In preclinical xenograft models, UBX-363 has shown dose-dependent tumor growth suppression and significant reduction of LCK protein levels in tumor tissues.